News

Expression and Codon Usage Enhance CRISPR Efficiency Prediction

A study by researchers at Tel Aviv University introduces new predictive features based on codon usage bias (CUB) and gene expression that significantly improve the accuracy of CRISPR efficiency predictions. By incorporating these features into existing predictive models, the study enhances the models’ ability to forecast the effectiveness of CRISPR editing across different cell types.

By: Gorm Palmgren - Sep. 3, 2024
News

The research addresses a key limitation in CRISPR technology: the challenge of designing guide RNAs (gRNAs) that are both highly efficient and specific to their target sites. Traditional predictive models primarily rely on sequence-based features, which often fall short in predicting CRISPR efficiency.

In contrast, the new study explores features derived from the genomic position of the target site, particularly focusing on nearby gene expression and codon usage. These features were found to perform comparably to, or better than, many state-of-the-art sequence-based features.

Using data from T cells, HEK293 cells, and U2OS cells, the researchers demonstrated that these CUB and expression features correlate strongly with CRISPR efficiency. When integrated into predictive models, these features led to significant improvements, boosting predictive accuracy by up to 39%.

The study concludes that incorporating such features, which are relatively easy to calculate and widely applicable, could greatly enhance our understanding and application of CRISPR technology in various biological contexts.

This research was conducted by Shaked Bergman and Tamir Tuller at Tel Aviv University, Israel, and it was published in Systems Biology and Applications on 3 September 2024.

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNews

News: Expression and Codon Usage Enhance CRISPR Efficiency Prediction
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Chronic Hepatitis B, HBV, (NCT06680232)
Sponsors:
Precision BioSciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine